CANbridge Pharmaceuticals Inc. Stock price

Equities

1228

KYG1821D1097

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.305 HKD 0.00% Intraday chart for CANbridge Pharmaceuticals Inc. -1.61% -69.19%

Financials

Sales 2023 * 76.95M 10.65M 83.35M Sales 2024 * 135M 18.71M 146M Capitalization 120M 16.57M 130M
Net income 2023 * -419M -57.99M -454M Net income 2024 * -365M -50.51M -395M EV / Sales 2023 * -1.43 x
Net cash position 2023 * 230M 31.85M 249M Net cash position 2024 * 510M 70.57M 552M EV / Sales 2024 * -2.89 x
P/E ratio 2023 *
-0.28 x
P/E ratio 2024 *
-0.33 x
Employees 118
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.49%
More Fundamentals * Assessed data
Dynamic Chart
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares MT
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee CI
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress CI
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration CI
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China CI
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome CI
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows MT
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment MT
CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart in Paroxysmal Nocturnal Hemoglobinuria CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call
CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome CI
CANbridge Pharmaceuticals Gets China Marketing Approval for Liver Disease Medication MT
CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) EMBARK Phase 2 Study in Biliary Atresia CI
More news

Latest transcript on CANbridge Pharmaceuticals Inc.

1 week-1.61%
Current month-27.38%
1 month-27.38%
3 months-69.50%
6 months-77.57%
Current year-69.19%
More quotes
1 week
0.28
Extreme 0.28
0.31
1 month
0.25
Extreme 0.25
0.50
Current year
0.25
Extreme 0.25
1.09
1 year
0.25
Extreme 0.25
2.03
3 years
0.25
Extreme 0.25
9.99
5 years
0.25
Extreme 0.25
9.99
10 years
0.25
Extreme 0.25
9.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 18-01-29
Director of Finance/CFO 46 19-04-01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 61 22-07-04
Director/Board Member 70 18-07-17
Director/Board Member 61 21-06-10
More insiders
Date Price Change Volume
24-03-28 0.305 0.00% 96 000
24-03-27 0.305 0.00% 14,000
24-03-26 0.305 0.00% 8,000
24-03-25 0.305 0.00% 7,000
24-03-22 0.305 -4.69% 43,000

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.305 HKD
Average target price
8.85 HKD
Spread / Average Target
+2,801.64%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock CANbridge Pharmaceuticals Inc. - Hong Kong S.E.